718-719 / 1674
University Hospital Erlangen
Results of APBI using brachytherapy
Author/Study
Number
of pts
(n)
Median follow-up
(years)
Local recurrences
(%)
(95% CI) (n)
Annual local
recurrences
%
Polgar et al., 2012
Hungarian National Institute of Oncology, Phase II, Budapest
45
13,8
11.9
(15 y.)
0,79
Johansson et al. , 2009
Örebro Med. Centre, Phase II, Örebro
50
7,2
4.0
0,57
King, Kuske et al., 2000
Ochsner Clinic, Phase II, New Orleans
51
6,25
2.0
0,32
Polgar et al , 2013
Hungarian National Institute of Oncology, Phase 3, Budapest
88*/258
* treated with brachytherapy
10,8
5.9
0,59
Arthur et al., 2008
Multicentric Phase II, RTOG 95-17
99
7
6.1
0,87
Mark et al., 2009
J Arrington Cancer Center, Phase II, Lubbock
192
5,4
4.2
0,78
Antonucci, Vicini et al. , 2011
William Beaumont Hospital, Phase II, Detroit, Match Pair analysis
199
9,6
5.0
0,52
Strnad et al., 2012
Multicentric Phase II, German-Austrian Study,
274
8
2.9
0,55
Wilkinson, Beitsch… Chen, Vicini et al.
[diffAPBI techniques]
2012 San Antonio Breast Cancer Symposium
2.127
6
4.0
0,66
Chen et al., ABS Annual Meeting 2014
W.Beaumont Health System, Royal Oak
484
8
1,3-2.5
0,25
-0,5
Young et al., ABS Annual Meeting 2014
Cancer Center, Oklahoma City
241
5,5
1.54
0,28
Kamrava, Kuske et al., 2015, Retrospective Analysis
1356
6,7
4.0
0,60
Strnad, Polgar et al. 2016 Phase 3 GEC-ESTRO trial
1184
6,6
1.44
0,21
Wobb JL et al, 2016
William Beaumont Hospital, Phase II, Detroit, Match Pair analysis
274
10
4%
0,40
TOTAL
4.686